Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple‐treatments meta‐analysis

  title={Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple‐treatments meta‐analysis},
  author={Demetria M. Taylor and Victoria R. Cornelius and L. A. Smith and A. H. Young},
  journal={Acta Psychiatrica Scandinavica},
Treatment of bipolar depression is complicated by variable response and risk of switch to mania. Guidance is informed by the strength of evidence rather than by comparative data. 

Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis

The objective of the current qualitative and quantitative review was to determine the overall antidepressant effect of adjunctive anti‐inflammatory agents in the treatment of bipolar depression.

Lurasidone versus typical antipsychotics for schizophrenia

This is a protocol for a Cochrane Review (Intervention) to review the efficacy and safety of lurasidone versus typical antipsychotics for adults with schizophrenia or related disorders.

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

There is emerging evidence that glutamatergic system dysfunction might play an important role in the pathophysiology of bipolar depression. This review focuses on the use of glutamate receptor

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

In this Bayesian network meta-analysis of AAP monotherapy in adults with bipolar depression, which evaluated change in depressive symptoms across short-term trials, the largest improvement versus placebo was observed for lurasidone, olanzapine and quetiapine.

Comparison of the efficacy and safety of quetiapine and lithium for bipolar depression: A systematic review and meta-analysis of randomized controlled trials.

Although this study found no differences in the efficacy and safety of quetiapine and lithium for bipolar depression, a comprehensive comparison of antipsychotics and mood stabilizers was not performed.

The Treatment of Bipolar Depression: Current Status and Future Perspectives

Ketamine represents a major breakthrough, producing rapid reductions in depressive symptoms even in cases of treatment-resistance, but challenges remain in how best to maintain response and reduce unwanted side effects.

Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder

The authors conclude that the real question is not whether ADs should or should not be used in bipolar depression, but which patients benefit from these drugs and which ones are impaired.

Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review

On the balance of efficacy and tolerability, LTG might be considered a first-line drug for BD, except for acute manic episodes or where rapid symptom control is required, but in terms of efficacy alone, the evidence favours other medications.



Long‐term antidepressant treatment in bipolar disorder: meta‐analyses of benefits and risks

Objective:  Long‐term antidepressant (AD) treatment for depression in bipolar disorder (BPD) patients is highly prevalent, but its benefits and risks remain uncertain, encouraging this meta‐analysis

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study

To investigate whether the cox‐2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases, a new drug is developed that combines the former and the latter into a single pill.

Previous mood state predicts response and switch rates in patients with bipolar depression

The role for antidepressant (AD) agents vs. mood stabilizers has been particularly problematic to ascertain and this work aims to clarify this role.

Lithium response in unipolar versus bipolar depression.

The antidepressant effects of lithium carbonate were evaluated in a group of 52 hospitalized depressed patients, using a longitudinal double-blind design that involved alternating drug and placebo

The use of lithium in affective disorders. I. Acute endogenous depression.

After two to three weeks, there was evidence of a moderate to strong antidepressant effect of imipramine, while lithium produced only a weak to mild antidepressant effect.

Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study

Olanzapine is effective in the treatment of bipolar I depression but is associated with significant metabolic side effects.

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.

Lamotrigine was found effective and safe as add-on treatment to lithium in the acute treatment of bipolar depression.

Unipolar and bipolar depression: different of the same?

The diagnostic boundary between recurrent unipolar depression and bipolar disorder may not be clear-cut and, further, the symptoms of unipolar depression compared with bipolar depression (although

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.

Lamotrigine monotherapy did not demonstrate efficacy in the acute treatment of bipolar depression in four out of five placebo-controlled clinical studies, but was well tolerated inThe results of five randomized, double-blind, placebo- controlled trials of lamotrigin monotherapy were reported.